论文部分内容阅读
本研究的目的是制备一种新的放射性药物,探讨其作为骨软骨显像剂的可能性。该方法采用亚锡还原法标记硫酸软骨素(Chondroitin sulfate,CS),其标记率及放射化学纯度分别为79.30%±1.72%和90.12%±1.23%。动态观察99mTc-CS在动物体内不同时相的生物学资料,表明该显像剂从血液清除快,主要经肾脏排泄,亲软骨组织特性较好。建立兔骨关节炎模型,于耳缘静脉注射99mTc-CS后5h进行静态影像,得到的显像图片清晰,病灶摄取显像剂明显增多,利用勾画感兴趣区技术计算病变关节与对侧正常组织(T/NT)的放射性计数比值为3.0±0.6(P<0.05)。结果表明99mTc-CS的标记方法简便,亲软骨组织性能良好,有待发展成为一种新的骨关节软骨显像剂。
The purpose of this study was to prepare a new radiopharmaceutical to investigate its potential as an osteochondral imaging agent. Chondroitin sulfate (CS) was labeled with stannous reduction method, and its labeling efficiency and radiochemical purity were 79.30% ± 1.72% and 90.12% ± 1.23%, respectively. Dynamic observation of the biological data of 99mTc-CS in different phases of animals showed that the imaging agent cleared from the bloodstream and was mainly excreted by the kidneys. The characteristics of the pro-cartilage tissue were better. Rabbit osteoarthritis model was established. Static images were obtained 5h after injection of 99mTc-CS in the ear vein. The imaging images obtained were clear and the imaging agents of the lesions were obviously increased. The lesions were calculated using the technique of drawing the ROI to calculate the lesion joints and contralateral normal tissues (T / NT) was 3.0 ± 0.6 (P <0.05). The results showed that 99mTc-CS labeling method is simple, pro-chondrogenic tissue performance is good, to be developed into a new osteoarticular imaging agent.